Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal! AI is eating the world—and the machines behind it are ravenous. Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink. Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and b ...

In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Johnson & Johnson is one of them. Johnson & Johnson (NYSE:JNJ), a global healthcare leader, continues to strengthen its pharmaceuticals and immunology portfolio while delivering strong stock performance in 2025. This month, the company received FDA approval for a subcutaneous induction regimen of Tremfya (guselkumab) to treat adults with ulcerative colitis. As the first and only IL-23 inhibitor with a ...

Tylenol once survived a poisoning scandal. Now it has to survive President Donald Trump. Kenvue, the company behind the household brand, at least has a playbook to turn to for guidance. That's because Tylenol's original owner, Johnson & Johnson, developed it decades ago after seven people in the Chicago area died from taking its capsules because someone had laced them with potassium cyanide. The 1982 unsolved mystery became known as the "Tylenol murders."J&J's handling of the incident not only saved the br ...

Experts from the WHO and other national health organizations emphasized that there is no conclusive evidence tying paracetamol, also known as acetaminophen, to autism or ADHD, despite President Trump’s claims this week.SUMMIT, NJ: Global health officials are repudiating President Donald Trump’s unproven medical claim that Tylenol’s active ingredient, acetaminophen, is linked to autism. Trump and Health and Human Services Secretary Robert F. Kennedy Jr. issued a warning on Monday claiming that prenatal expos ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.Top 5 Upgrades: Jefferies upgraded Onto Innovation (ONTO) to Buy from Hold with a price target of $170, up from $100. The firm tells investors to look past the company's near term "hurdles" as its growth will reaccelerate in the second half of 2026.Bernstein upgraded United Rentals (URI) to Outperform from Market Perform with a p ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.Citigroup analyst Paul Diamond upgraded Antero Resources Corporation AR from Neutral to Buy and raised the price target from $37 to $39. Antero Resources shares closed at $32.58 on Monday. See how other analysts view this stock.Wells Fargo analyst Michael Turrin upgraded CoreWeave, Inc. CRWV from Equal-Weight ...

U.S. stock futures presented a mixed picture in premarket trading on Tuesday, September 23, 2025, as investors digested a flurry of corporate news and awaited key economic signals, most notably a speech from Federal Reserve Chair Jerome Powell. This follows a robust Monday session where major indices notched their third consecutive day of record closing highs, largely propelled by optimism surrounding artificial intelligence and expectations of further Federal Reserve rate cuts.Premarket Trading Activity an ...

Johnson & Johnson's (NYSE:JNJ) market capitalization increased by $63 billion in the past three months, driven by a 17.7% rise in share price.Innovative Medicine sales rose by 2.4%, despite the expiration of Stelara's patent, showcasing the company's resilience and innovation.MedTech sales growth of 6.1%, supported by acquisitions and new product launches, highlights the company's expanding market presence.On September 22, 2025, Johnson Rice upgraded Johnson & Johnson (NYSE:JNJ) to a "Buy" rating, with the ...

Johnson & Johnson will withdraw a device to treat acid reflux disease from markets outside the U.S., Bloomberg News reported on Tuesday, citing a company letter sent to doctors. ...

(Bloomberg) -- Johnson & Johnson is withdrawing a device to treat debilitating acid reflux disease from markets outside the US, a move surgeons warned would set back the available treatment options for sufferers by more than a decade and also impact lung transplant patients. Sales of the Linx Reflux Management System will be stopped outside the US from the end of March, the company said in a letter to doctors dated Sept. 17 seen by Bloomberg. J&J confirmed it was stopping sales in “certain countries,” bas ...